febuxostat has been researched along with olanzapine in 2 studies
| Studies (febuxostat) | Trials (febuxostat) | Recent Studies (post-2010) (febuxostat) | Studies (olanzapine) | Trials (olanzapine) | Recent Studies (post-2010) (olanzapine) |
|---|---|---|---|---|---|
| 818 | 133 | 710 | 6,339 | 1,340 | 2,383 |
| Protein | Taxonomy | febuxostat (IC50) | olanzapine (IC50) |
|---|---|---|---|
| 5-hydroxytryptamine receptor 4 | Cavia porcellus (domestic guinea pig) | 0.097 | |
| Muscarinic acetylcholine receptor M4 | Homo sapiens (human) | 0.155 | |
| 5-hydroxytryptamine receptor 2C | Rattus norvegicus (Norway rat) | 0.047 | |
| Muscarinic acetylcholine receptor M5 | Homo sapiens (human) | 0.04 | |
| Alpha-2A adrenergic receptor | Homo sapiens (human) | 0.541 | |
| Polyunsaturated fatty acid lipoxygenase ALOX15 | Oryctolagus cuniculus (rabbit) | 2.768 | |
| D(2) dopamine receptor | Homo sapiens (human) | 0.118 | |
| 5-hydroxytryptamine receptor 2A | Rattus norvegicus (Norway rat) | 0.047 | |
| Alpha-2B adrenergic receptor | Homo sapiens (human) | 0.421 | |
| Alpha-2C adrenergic receptor | Homo sapiens (human) | 0.531 | |
| Muscarinic acetylcholine receptor M3 | Homo sapiens (human) | 0.392 | |
| D(1A) dopamine receptor | Homo sapiens (human) | 0.072 | |
| D(4) dopamine receptor | Homo sapiens (human) | 0.173 | |
| Alpha-1D adrenergic receptor | Homo sapiens (human) | 0.092 | |
| 5-hydroxytryptamine receptor 2A | Homo sapiens (human) | 0.038 | |
| 5-hydroxytryptamine receptor 2C | Homo sapiens (human) | 0.021 | |
| 5-hydroxytryptamine receptor 2B | Rattus norvegicus (Norway rat) | 0.047 | |
| Sodium-dependent serotonin transporter | Homo sapiens (human) | 1.033 | |
| Histamine H1 receptor | Homo sapiens (human) | 0.013 | |
| D(3) dopamine receptor | Homo sapiens (human) | 0.078 | |
| 5-hydroxytryptamine receptor 2B | Homo sapiens (human) | 0.057 | |
| 5-hydroxytryptamine receptor 6 | Homo sapiens (human) | 0.013 | |
| D(2) dopamine receptor | Rattus norvegicus (Norway rat) | 0.158 | |
| Potassium voltage-gated channel subfamily H member 2 | Homo sapiens (human) | 0.2028 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
1 review(s) available for febuxostat and olanzapine
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
1 other study(ies) available for febuxostat and olanzapine
| Article | Year |
|---|---|
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |